{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:03Z","timestamp":1793159103626,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"\n Importance<\/jats:title>\n Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the effect of tafamidis on cardiac function in patients with ATTR-CM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (\u226550%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (\u226440%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E\/e\u2032) were compared in patients receiving tafamidis, 80 mg, vs placebo.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n\u2009=\u2009176), vs placebo (n\u2009=\u2009177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49;\n P<\/jats:italic>\n \u2009=\u2009.002; LV global longitudinal strain, \u22121.02%; 95% CI, \u22121.73 to \u22120.31;\n P<\/jats:italic>\n \u2009=\u2009.005; septal E\/e\u2032, \u22123.11; 95% CI, \u22125.50 to \u22120.72;\n P<\/jats:italic>\n \u2009=\u2009.01; lateral E\/e\u2032, \u22122.35; 95% CI, \u22124.01 to \u22120.69;\n P<\/jats:italic>\n \u2009=\u2009.006).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01994889<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.4147","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:01:31Z","timestamp":1700046091000},"page":"25","source":"Crossref","is-referenced-by-count":87,"title":["Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1001","volume":"9","author":[{"given":"Sanjiv J.","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan L.","family":"Klein","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Heart Institute, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Weissman","sequence":"additional","affiliation":[{"name":"Medstar Health Research Institute, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Boman","sequence":"additional","affiliation":[{"name":"Research Unit, Skellefte\u00e5 County Hospital, Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balarama","family":"Gundapaneni","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla B.","family":"Sultan","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"hoi230058r1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi230058r2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice.","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"1","key":"hoi230058r3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"38","key":"hoi230058r4","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi230058r5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi230058r6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"10","key":"hoi230058r7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management.","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"issue":"14","key":"hoi230058r8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"hoi230058r9","doi-asserted-by":"publisher","first-page":"A16145","DOI":"10.1161\/circ.142.suppl_3.16145","article-title":"Abstract 16145: reduced ejection fraction at diagnosis is an independent predictor of mortality in transthyretin amyloid cardiomyopathy.","volume":"142","author":"Bukhari","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"hoi230058r10","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"hoi230058r11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi230058r12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"hoi230058r13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"issue":"8","key":"hoi230058r14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"hoi230058r16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).","volume":"10","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"4","key":"hoi230058r17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hoi230058r18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"hoi230058r19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.v23.3","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"issue":"2","key":"hoi230058r20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.v23.2","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"hoi230058r21","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"hoi230058r22","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"5","key":"hoi230058r23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study.","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"4","key":"hoi230058r24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/CIRCULATIONAHA.118.037593","article-title":"Targeted therapeutics for transthyretin cardiac amyloidosis.","volume":"139","author":"Shah","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"hoi230058r25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14?333 African-Americans.","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"hoi230058r26","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.v8.5","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"10","key":"hoi230058r27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"hoi230058r28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/heartjnl-2019-316215","article-title":"Global longitudinal strain: clinical use and prognostic implications in contemporary practice.","volume":"106","author":"Abou","year":"2020","journal-title":"Heart"},{"issue":"15","key":"hoi230058r29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/eurheartj\/ehv529","article-title":"Myocardial strain imaging: how useful is it in clinical decision making?","volume":"37","author":"Smiseth","year":"2016","journal-title":"Eur Heart J"},{"key":"hoi230058r15","unstructured":"Pfizer. Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) prescribing information. Accessed December 4, 2022. https:\/\/www.fda.gov\/media\/126283\/download"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2811926\/jamacardiology_shah_2023_oi_230058_1703114493.29548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T11:01:54Z","timestamp":1704884514000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2811926"}},"subtitle":["A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.4147","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}